JP5468782B2 - 癌治療と幹細胞調節のための方法 - Google Patents

癌治療と幹細胞調節のための方法 Download PDF

Info

Publication number
JP5468782B2
JP5468782B2 JP2008557240A JP2008557240A JP5468782B2 JP 5468782 B2 JP5468782 B2 JP 5468782B2 JP 2008557240 A JP2008557240 A JP 2008557240A JP 2008557240 A JP2008557240 A JP 2008557240A JP 5468782 B2 JP5468782 B2 JP 5468782B2
Authority
JP
Japan
Prior art keywords
cells
cell
deazaneplanocin
prc2
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008557240A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009528345A5 (enExample
JP2009528345A (ja
Inventor
ユ、チアン
タン、ジン
ジン ヤン、シャオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agency for Science Technology and Research Singapore
Original Assignee
Agency for Science Technology and Research Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency for Science Technology and Research Singapore filed Critical Agency for Science Technology and Research Singapore
Publication of JP2009528345A publication Critical patent/JP2009528345A/ja
Publication of JP2009528345A5 publication Critical patent/JP2009528345A5/ja
Application granted granted Critical
Publication of JP5468782B2 publication Critical patent/JP5468782B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2008557240A 2006-03-02 2006-11-15 癌治療と幹細胞調節のための方法 Expired - Fee Related JP5468782B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77853206P 2006-03-02 2006-03-02
US60/778,532 2006-03-02
PCT/SG2006/000350 WO2007100304A1 (en) 2006-03-02 2006-11-15 Methods for cancer therapy and stem cell modulation

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2013015684A Division JP2013121974A (ja) 2006-03-02 2013-01-30 癌治療と幹細胞調節のための方法
JP2013213366A Division JP5902138B2 (ja) 2006-03-02 2013-10-11 癌治療と幹細胞調節のための方法

Publications (3)

Publication Number Publication Date
JP2009528345A JP2009528345A (ja) 2009-08-06
JP2009528345A5 JP2009528345A5 (enExample) 2010-01-07
JP5468782B2 true JP5468782B2 (ja) 2014-04-09

Family

ID=38459334

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2008557240A Expired - Fee Related JP5468782B2 (ja) 2006-03-02 2006-11-15 癌治療と幹細胞調節のための方法
JP2013015684A Pending JP2013121974A (ja) 2006-03-02 2013-01-30 癌治療と幹細胞調節のための方法
JP2013213366A Expired - Fee Related JP5902138B2 (ja) 2006-03-02 2013-10-11 癌治療と幹細胞調節のための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013015684A Pending JP2013121974A (ja) 2006-03-02 2013-01-30 癌治療と幹細胞調節のための方法
JP2013213366A Expired - Fee Related JP5902138B2 (ja) 2006-03-02 2013-10-11 癌治療と幹細胞調節のための方法

Country Status (7)

Country Link
US (2) US8058258B2 (enExample)
EP (2) EP1993553B1 (enExample)
JP (3) JP5468782B2 (enExample)
AU (1) AU2006339445A1 (enExample)
SG (1) SG170041A1 (enExample)
TW (1) TW200812590A (enExample)
WO (1) WO2007100304A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG185942A1 (en) * 2007-11-02 2012-12-28 Agency Science Tech & Res Methods and compounds for preventing and treating a tumour
US8629275B2 (en) 2008-09-08 2014-01-14 Merck Sharp & Dohme Corp. AHCY hydrolase inhibitors for treatment of hyper homocysteinemia
EP2331543A4 (en) * 2008-09-26 2013-06-19 Agency Science Tech & Res 3-deazaneplanocin DERIVATIVES
WO2010111712A2 (en) * 2009-03-27 2010-09-30 Cold Spring Harbor Laboratory Identification of rnai targets and use of rnai for rational therapy of chemotherapy-resistant leukemia and other cancers
US8491927B2 (en) 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
SG180031A1 (en) * 2010-10-15 2012-05-30 Agency Science Tech & Res Combination treatment of cancer
WO2012082436A2 (en) * 2010-12-03 2012-06-21 Epizyme, Inc. Modulators of histone methyltransferase, and methods of use thereof
RU2606514C2 (ru) 2010-12-03 2017-01-10 Эпизайм, Инк. Замещенные пуриновые и 7-деазапуриновые соединения
WO2012075500A2 (en) 2010-12-03 2012-06-07 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
EP2709612A4 (en) * 2011-05-19 2015-07-01 Glax L L C COMPOSITIONS AND METHODS OF TREATMENT AND PREVENTION OF CANCER BY TARGETING AND INHIBITION OF CANCER STEM CELLS
WO2013036846A2 (en) * 2011-09-09 2013-03-14 Koronis Pharmaceuticals, Incorporated N4 derivatives of deoxycytidine prodrugs
EP2869852A4 (en) * 2012-07-09 2016-04-20 Metheor Therapeutics Corp Oligonucleotide inhibitors of DNA methyltransferases and their use in the treatment of diseases
WO2014026198A1 (en) 2012-08-10 2014-02-13 Epizyme, Inc. Inhibitors of protein methyltransferase dot1l and methods of use thereof
EP2892536B1 (en) 2012-09-06 2019-12-18 Epizyme, Inc. Method of treating leukemia
WO2014062978A1 (en) * 2012-10-17 2014-04-24 Cedars-Sinai Medical Center Molecular signatures of ovarian cancer
US20160010059A1 (en) * 2013-03-06 2016-01-14 The Regents Of The University Of California EXPANSION OF HEMATOPOIETIC PROGENITOR CELLS BY HISTONE METHYLTRANSFERASE G9a INHIBITION
US9175032B2 (en) 2013-03-15 2015-11-03 Epizyme, Inc. Methods of synthesizing substituted purine compounds
WO2016022563A1 (en) 2014-08-04 2016-02-11 Auburn University Enantiomers of the 1',6'-isomer of neplanocin a
US20160271149A1 (en) * 2015-03-16 2016-09-22 Epinova Therapeutics Corp. Therapeutic compounds that suppress protein arginine methyltransferase activity for reducing tumor cell proliferation
WO2020055663A1 (en) * 2018-09-11 2020-03-19 The Texas A&M University System L-oligonucleotide inhibitors of polycomb repressive complex 2 (prc2)
WO2020057107A1 (zh) * 2018-09-17 2020-03-26 诺未科技（北京）有限公司 一种组合物及其用途
WO2023249714A1 (en) * 2022-06-24 2023-12-28 Memorial Sloan-Kettering Cancer Center Therapeutic compositions and methods for activating double stranded rna response in cancer patients via dnmt1 targeted therapy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US510260A (en) 1893-12-05 Electric-arc-lighting system
US4968690A (en) 1986-05-27 1990-11-06 United States Government As Represented By The Secretary Of The Dept. Of Health And Human Services 3-deazaneplanocin, intermediates for it, and antiviral composition and method of treatment using it
US4975434A (en) 1986-05-27 1990-12-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antiviral and anticancer cyclopentenyl cytosine
JPH04327587A (ja) 1991-04-26 1992-11-17 Asahi Chem Ind Co Ltd ６’−ｃ−アルキル−３−デアザネプラノシンａ誘導体、その製造法およびその用途
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US6090622A (en) 1997-03-31 2000-07-18 The Johns Hopkins School Of Medicine Human embryonic pluripotent germ cells
DK1064027T3 (da) 1998-03-27 2008-09-08 Genentech Inc APO-2 Ligand-anti-her-2-antistofsynergier
SE517975C2 (sv) 2000-05-30 2002-08-13 Power Ab C Fackverkskonstruktion av balkar sammansatta till ett tredimensionellt ramverk samt användning av en sådan fackverkskonstruktion
US20050191618A1 (en) 2001-05-18 2005-09-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA)
EP1536688B1 (en) 2002-09-13 2011-12-28 The Board Of Trustees Of The Leland Stanford Junior University Mammalian megakaryocyte progenitor cell
AU2003295444A1 (en) 2002-11-15 2004-06-15 The Board Of Trustees Of The University Of Illinois Methods for in vitro expansion of hematopoietic stem cells
US20050245559A1 (en) 2004-01-23 2005-11-03 Koul Hari K Treatment and prevention of prostate cancer
US20050266093A1 (en) 2004-04-27 2005-12-01 Mohapatra Shyam S Nanogene therapy for cell proliferation disorders
CA2574176A1 (en) 2004-07-20 2006-02-09 Schering Corporation Induction of apoptosis in toll-like receptor expressing tumor cells

Also Published As

Publication number Publication date
EP2522352B1 (en) 2017-01-11
EP1993553A4 (en) 2010-07-28
US20120077841A1 (en) 2012-03-29
JP2009528345A (ja) 2009-08-06
US8058258B2 (en) 2011-11-15
US8211869B2 (en) 2012-07-03
EP1993553B1 (en) 2013-05-08
AU2006339445A1 (en) 2007-09-07
JP2013121974A (ja) 2013-06-20
TW200812590A (en) 2008-03-16
EP1993553A1 (en) 2008-11-26
WO2007100304A1 (en) 2007-09-07
JP5902138B2 (ja) 2016-04-13
SG170041A1 (en) 2011-04-29
US20100075915A1 (en) 2010-03-25
EP2522352A1 (en) 2012-11-14
JP2014028853A (ja) 2014-02-13

Similar Documents

Publication Publication Date Title
JP5902138B2 (ja) 癌治療と幹細胞調節のための方法
Liu et al. HDAC1 silencing in ovarian cancer enhances the chemotherapy response
US20090137517A1 (en) Sensitizing a cell to cancer treatment by modulating the activity of a nucleic acid encoding rps27l protein
Zarredar et al. Critical microRNAs in lung cancer: recent advances and potential applications
US12516318B2 (en) Targeting glioblastoma stem cells through the TLX-TET3 axis
Chai et al. Downregulation of BRCA1-BRCA2-containing complex subunit 3 sensitizes glioma cells to temozolomide
Li et al. MiR-214 regulates oral cancer KB cell apoptosis through targeting RASSF5
Wang et al. Tumor suppressors microRNA-302d and microRNA-16 inhibit human glioblastoma multiforme by targeting NF-κB and FGF2
CN108165632B (zh) Linc01426在肝细胞癌诊断和治疗中的应用
CN114574580A (zh) 靶向a2br联合化疗在三阴性乳腺癌治疗中的应用
EP4299742A1 (en) Combination therapy for melanoma
CN113930423B (zh) 保护心肌细胞免受应激损伤的saRNA及其应用
CN105163741A (zh) 包含dna甲基化抑制剂的常染色体显性多囊肾改善或治疗用药学组合物
WO2024003350A1 (en) Combination therapy for melanoma
Hosseini DISSECTING THE ROLE OF LYSINE-SPECIFIC DEMETHYLASE1 (LSD1): IDENTIFICATION OF MARKERS/EFFECTORS OF SENSITIVITY TO LSD1 INHIBITORS IN CANCER.
Costa Role of miR-29b in the regulation of progranulin and dna methyltransferases 3A and 3B expression: therapeutic potential in glioblastoma
WO2021209608A1 (en) Medical methods and medical uses
WO2026013071A1 (en) Setdb1 inhibitor for use in the treatment of uveal melanoma
TWI585204B (zh) 用以治療癌症之短干擾核糖核酸分子
Chen-Tian et al. miRNA-106a directly targeting RARB associates with the expression of Na+/I-symporter in thyroid cancer by regulating MAPK signaling pathway
WO2020153503A1 (ja) ＳＮＨＧ１２遺伝子に由来するｎｃＲＮＡの発現抑制剤を有効成分とするがん増殖抑制剤
Garcia et al. Identification of Novel Therapeutic Targets in Glioblastoma
JPWO2020040185A1 (ja) Ｈｓｐ４７の阻害物質を用いた、化学療法剤感受性の増強
WO2011112607A2 (en) NKX3-1 saRNA AND KLF4 saRNA AND USES THEREOF
Mio Analysis of the biological mechanisms de-regulated after pharmacological BET inhibition in a model of anaplastic thyroid cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091111

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120807

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121107

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121114

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121206

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130104

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130130

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131011

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20131216

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140130

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees